Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TThi, Chaudhary N, Riely GJ, Li BT, Scott K et al..  2017.  An approach to suppress the evolution of resistance in BRAF-mutant cancer.. Nat Med. 23(8):929-937.

Mondello P, Derenzini E, Asgari Z, Philip J, Brea EJ, Seshan V, Hendrickson RC, de Stanchina E, Scheinberg DA, Younes A.  2017.  Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.. Oncotarget. 8(8):14017-14028.

Reinartz R, Wang S, Kebir S, Silver DJ, Wieland A, Zheng T, Küpper M, Rauschenbach L, Fimmers R, Shepherd TM et al..  2017.  Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma.. Clin Cancer Res. 23(2):562-574.

Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M et al..  2017.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.. Nature. 546(7658):431-435.

Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M et al..  2017.  A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.. J Clin Invest. 127(7):2705-2718.

Röhrig F, Vorlová S, Hoffmann H, Wartenberg M, Escorcia FE, Keller S, Tenspolde M, Weigand I, Gätzner S, Manova K et al..  2017.  VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.. Oncogene. 36(1):1-12.

Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ et al..  2015.  CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.. Cancer Cell. 28(1):15-28.

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E et al..  2013.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.. Science. 340(6132):626-30.

Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, Hong S-M, Zhao M, Rudek MA, Khan SR et al..  2012.  A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists.. Mol Cancer Ther. 11(1):165-73.